These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32101674)

  • 1. Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply.
    Hellmann MD; Ramalingam SS
    N Engl J Med; 2020 Feb; 382(9):875. PubMed ID: 32101674
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
    Bersanelli M; Tiseo M; Banna GL
    N Engl J Med; 2020 Feb; 382(9):874-875. PubMed ID: 32101673
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
    Kim J; Shin SW
    N Engl J Med; 2020 Feb; 382(9):874. PubMed ID: 32101672
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab plus ipilimumab in non-small-cell lung cancer.
    Reck M; Borghaei H; O'Byrne KJ
    Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg; 2024 Apr; 167(4):1454-1455. PubMed ID: 38340115
    [No Abstract]   [Full Text] [Related]  

  • 6. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply.
    Gettinger S; Redman MW; Herbst RS
    JAMA Oncol; 2022 Apr; 8(4):1. PubMed ID: 35142793
    [No Abstract]   [Full Text] [Related]  

  • 7. High TMB Predicts Immunotherapy Benefit.
    Cancer Discov; 2018 Jun; 8(6):668. PubMed ID: 29661758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M
    J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    Zhao B; Ma W
    JAMA Oncol; 2022 Apr; 8(4):641-642. PubMed ID: 35142796
    [No Abstract]   [Full Text] [Related]  

  • 10. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    Gil-Sierra MD; Del Pilar Briceño-Casado M; Sánchez-Hidalgo M
    JAMA Oncol; 2022 Apr; 8(4):642. PubMed ID: 35142795
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
    Ito M; Fujiwara S; Fujimoto D; Mori R; Yoshimura H; Hata A; Kohara N; Tomii K
    Ann Oncol; 2017 Sep; 28(9):2318-2319. PubMed ID: 28911080
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
    Oya M; Tajima Y; Kabu K
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 16. Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors.
    Cancer Discov; 2018 Mar; 8(3):263. PubMed ID: 29420181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.
    Killock D
    Nat Rev Clin Oncol; 2018 Jul; 15(7):403. PubMed ID: 29703915
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply.
    Haratani K; Hayashi H; Nakagawa K
    JAMA Oncol; 2018 Jul; 4(7):1017-1018. PubMed ID: 29852041
    [No Abstract]   [Full Text] [Related]  

  • 19. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.